Pretreatment with chemotherapeutics for enhanced nanoparticles accumulation in tumor: The potential role of G2 cycle retention effect

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Gao, Huile ^a   Hu, Guanlian ^a   Zhang, Qianyu ^a   Zhang, Shuang ^b   Jiang, Xinguo ^b   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; NANOPARTICLE; TAXOID;

ANIMAL; CHEMISTRY; DRUG EFFECTS; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; NANOPARTICLES; NEOPLASMS; TAXOIDS; TISSUE DISTRIBUTION;

EID: 84897102433     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04492     Document Type: Article

References (46)

1. Siegel, R.,Naishadham,D.&Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013).
2. Lammers, T., Kiessling, F., Hennink, W. E. & Storm, G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161, 175-87 (2012).
3. Lammers, T., Hennink, W. E. & Storm, G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99, 392-7 (2008).
4. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-92 (1986).
5. Fang, J., Nakamura, H. & Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63, 136-51 (2011).
6. Barenholz, Y. C. Doxil(R)-The first FDA-approved nano-drug: Lessons learned. J. Control. Release 160, 117-34 (2012).
7. Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65, 71-9 (2013).
8. Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7, 653-64 (2010).
9. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-82 (2008).
10. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2, 751-60 (2007).
11. Byrne, J. D., Betancourt, T. & Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60, 1615-26 (2008).
12. Van der Meel, R., Vehmeijer, L. J., Kok, R. J., Storm, G. & van Gaal, E. V. Ligandtargeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv Drug Deliv Rev 65, 1284-1298 (2013).
13. Florence, A. T. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. J. Control. Release 164, 115-24 (2012).
14. Kirpotin, D. B. et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732-40 (2006).
15. Pirollo, K. F. & Chang, E. H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 26, 552-8 (2008).
16. Choi, C. H., Alabi, C. A.,Webster, P., Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107, 1235-40 (2010).
17. Gao, H. et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 3, 2534 (2013).
18. Mahmoudi,M., Azadmanesh, K., Shokrgozar, M. A., Journeay, W. S.& Laurent, S. Effect of nanoparticles on the cell life cycle. Chem. Rev. 111, 3407-32 (2011).
19. Lesniak, A. et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 6, 5845-57 (2012).
20. Zhang, H., Mardyani, S., Chan, W. C. & Kumacheva, E. Design of biocompatible chitosan microgels for targeted pH-mediated intracellular release of cancer therapeutics. Biomacromolecules 7, 1568-72 (2006).
21. Jiang, W., Kim, B. Y., Rutka, J. T. & Chan, W. C. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3, 145-50 (2008).
22. Kim, J. A., Aberg, C., Salvati, A. & Dawson, K. A. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. NatNanotechnol 7, 62-8 (2012).
23. Cheetham, P. & Petrylak, D. P. Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J. 19, 59-65 (2013).
24. Payton, S. Prostate cancer: Timing is everything for docetaxel therapy. Nat Rev Urol 10, 123 (2013).
25. Ramaswamy, B. & Puhalla, S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc) 42, 265-79 (2006).
26. Gao, H. et al. Study and evaluation of Mechanisms of Dual Targeting Drug Delivery System with TumorMicroenvironment Assays Compared with Normal Assays. Acta Biomater 10, 858-867 (2014).
27. Gao, H. et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33, 6264-72 (2012).
28. Miyoshi, N., Uchida, K., Osawa, T. & Nakamura, Y. A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogenactivated protein kinases in the Bcl-2 phosphorylation. Cancer Res. 64, 2134-42 (2004).
29. Emanuel, S. et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 65, 9038-46 (2005).
30. Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-4 (1998).
31. Stenseth, K., Thyberg, J. Monensin and chloroquine inhibit transfer to lysosomes of endocytosed macromolecules in cultured mouse peritoneal macrophages. Eur. J. Cell Biol. 49, 326-33 (1989).
32. Lamaze, C. & Schmid, S. L. The emergence of clathrin-independent pinocytic pathways. Curr. Opin. Cell Biol. 7, 573-80 (1995).
33. de Carcer, G., Perez, D. C. I. & Malumbres, M. Targeting cell cycle kinases for cancer therapy. Curr. Med. Chem. 14, 969-85 (2007).
34. Schwartz, G. K. & Shah, M. A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23, 9408-21 (2005).
35. Kim, S. Y., Lee, Y. M., Baik, D. J. & Kang, J. S. Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 24, 55-63 (2003).
36. Mitchison, T. & Kirschner, M. Dynamic instability of microtubule growth. Nature 312, 237-42 (1984).
37. Murray, J. W., Wolkoff, A. W. Roles of the cytoskeleton and motor proteins in endocytic sorting. Adv Drug Deliv Rev 55, 1385-403 (2003).
38. Rogers, S. L. & Gelfand, V. I. Membrane trafficking, organelle transport, and the cytoskeleton. Curr. Opin. Cell Biol. 12, 57-62 (2000).
39. Yvon, A. M., Wadsworth, P. & Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947-59 (1999).
40. Aniento, F., Emans, N., Griffiths, G. & Gruenberg, J. Cytoplasmic dyneindependent vesicular transport from early to late endosomes. J. Cell Biol. 123, 1373-87 (1993).
41. Lemasters, J. J. et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 4, 769-81 (2002).
42. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163 (2007).
43. Fu, Q. et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 4, 262-72 (2009).
44. Damascelli, B. et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92, 2592-602 (2001).
45. Sadauskas, E. et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 4, 10 (2007).
46. Gao, H. et al. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials 32, 8669-8675 (2011).